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Abstract: The chronically inflamed mucosa in patients with chronic rhinosinusitis (CRS) can
additionally be infected by bacteria, which results in an acute exacerbation of the disease (AECRS).
Currently, AECRS is universally treated with antibiotics following the guidelines for acute bacterial
rhinosinusitis (ABRS), as our understanding of its microbiology is insufficient to establish specific
treatment recommendations. Unfortunately, antibiotics frequently fail to control the symptoms of
AECRS due to biofilm formation, disruption of the natural microbiota, and arising antibiotic resistance.
These issues can potentially be addressed by phage therapy. In this study, the endoscopically-guided
cultures were postoperatively obtained from 50 patients in order to explore the microbiology of
AECRS, evaluate options for antibiotic treatment, and, most importantly, assess a possibility of efficient
phage therapy. Staphylococcus aureus and coagulase-negative staphylococci were the most frequently
isolated bacteria, followed by Haemophilus influenzae, Pseudomonas aeruginosa, and Enterobacteriaceae.
Alarmingly, mechanisms of antibiotic resistance were detected in the isolates from 46% of the patients.
Bacteria not sensitive to amoxicillin were carried by 28% of the patients. The lowest rates of resistance
were noted for fluoroquinolones and aminoglycosides. Fortunately, 60% of the patients carried
bacterial strains that were sensitive to bacteriophages from the Biophage Pharma collection and 81%
of the antibiotic-resistant strains turned out to be sensitive to bacteriophages. The results showed that
microbiology of AECRS is distinct from ABRS and amoxicillin should not be the antibiotic of first
choice. Currently available bacteriophages could be used instead of antibiotics or as an adjunct to
antibiotics in the majority of patients with AECRS.
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1. Introduction
According to recent studies, at least 1 in 10 citizens of Europe and the USA struggles with chronic
rhinosinusitis (CRS) [1,2]. Persistent symptoms that define the disease, such as nasal congestion and
discharge, facial pain, and loss of smell, can be even more debilitating than serious cardiovascular
or pulmonary problems [3]. Billions of dollars are spent yearly on antimicrobials for patients with
sinusitis and research on the subject [4,5], but surprisingly, it seems that many essential questions
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concerning the actual role of bacteria in CRS still remain unanswered. In this article, we discuss the
indications for antibacterial treatment in patients with CRS and investigate whether they could benefit
from bacteriophage therapy.
1.1. Antimicrobial Treatment in Patients with CRS
CRS is a multifactorial inflammatory disorder and currently it is no longer regarded as a primarily
infectious process [6]. Nevertheless, antibiotics are frequently prescribed for patients with CRS [7].
The rationales behind this line of treatment are as follows:
(1) Antibiotics are expected to alleviate the baseline symptoms of CRS, because they decrease the
load of bacteria that may supposedly play a role in perpetuating the inflammation [6];
(2) Antibiotics (or other novel antimicrobials) are hoped to reduce bacterial biofilms that contribute
to the recalcitrance of CRS [8–10];
(3) Antibiotics eliminate bacteria that cause acute exacerbations of CRS (AECRS) i.e., acute infections
that temporarily worsen the chronic symptoms.
As discussed below, the indications for antimicrobial therapy are best established in AECRS, while
the evidence supporting its use in the first two clinical situations is ambiguous.
(1) CRS (baseline symptoms).
The role of bacteria in the etiology of CRS is poorly understood [11]. Current studies have shown
that diverse microbial communities exist in the sinuses both in healthy subjects and in patients with
sinusitis [12,13]. The cause–effect relationship between the presence of bacteria and the symptoms of
CRS is usually far from apparent [14]. In fact, the etiology of CRS is very complex. In many patients
the symptoms can be caused by multiple other factors and the microorganisms dwelling in the sinuses
may have virtually no impact on the basic course of the disease. Therefore, therapy directed against
these bacteria does not result in clinical improvement [15].
It is possible that in the near future antimicrobials will find their place in the treatment of CRS.
Current understanding of sinonasal dysbiosis and its significance for the pathogenesis of the disease is
insufficient to introduce any rational antimicrobial therapy that could restore a beneficial microbiota.
(2) Biofilms.
Bacterial biofilms are associated with the most severe forms of rhinosinusitis [8–10]. Consortia of
microorganisms embedded in an extracellular matrix are 1000-fold more resistant to antibiotics than
planktonic bacteria [6]. Unfortunately, despite vigorous research, currently available antimicrobials are
unable to induce sufficient eradication of the sinonasal biofilms [16].
(3) Bacterial exacerbations of CRS (AECRS).
The causative role of bacteria seems to be most apparent in infectious exacerbations of CRS.
AECRS is defined as a sudden worsening of symptoms with a return to baseline symptoms after
treatment [17–19]. Exacerbations can be caused by bacteria or other factors (allergy, virus, etc.). During
an acute bacterial exacerbation, the aggravation of symptoms occurs when the chronically inflamed
mucosa is additionally temporarily invaded by bacteria. Bacterial etiology is usually suspected if there
is evidence of purulent secretions on nasal endoscopy [20,21]. Most experts agree that acute bacterial
exacerbations of CRS require antimicrobial treatment [6,22–24]. It is important to note that in this case
antimicrobials are not expected to cure CRS, but rather to clear out the symptoms of exacerbation and
help the patient to return to their “baseline severity” of the disease.
In the light of current evidence, patients with CRS are most likely to benefit from any kind of
culture-directed antimicrobial treatment when they present with signs of bacterial exacerbations. For
this reason, we chose this particular group of patients to investigate the possibility of introducing
phage therapy as an alternative for traditional antibiotic therapy.
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1.2. Bacteriophage Therapy Versus Antibiotic Therapy for AECRS
In clinical practice, antibiotic therapy of AECRS frequently proves ineffective or the patients
experience rapid recurrence of the infection. The disease can be recalcitrant to antibiotic treatment for
several reasons [6,11,24]:
• Increasing prevalence of antibiotic-resistant bacteria is observed in sinonasal infections worldwide;
• Biofilms that constitute a bacterial reservoir for recurrent exacerbations prove virtually impossible
to eradicate with antibiotics;
• Non-selective elimination of both pathogenic and potentially beneficial bacteria caused by
antibiotics results in uncontrolled repopulation of the empty niches. This process cannot be
controlled and may not lead to restoration of an ‘optimal’ microbial community. The role of
potential probiotics is still too poorly understood to prevent reintroduction of pathogenic species;
• Repeated courses of antibiotic therapy may contribute to increasing antibiotic resistance of the
patient’s microbiota;
• In some patients, antibiotics cause serious adverse effects or allergic reactions.
Bacteriophage therapy can potentially address the problems mentioned above. The bacteriophages
(or phages) are viruses that infect and destroy bacterial cells. They have been used in the treatment of
human infections for a hundred years now, however, in Western countries, they were all but forgotten
after the introduction of antibiotics [25,26].
The bacteriophages have several advantages compared to antibiotics [27,28]:
• The mechanisms of antibiotic and phage resistance are entirely different. Therefore, bacterial
strains that acquired antibiotic resistance frequently remain sensitive to phages;
• Some phages are able to penetrate and disrupt bacterial biofilms;
• The phages are highly selective. They eliminate only selected bacterial strains and leave the rest
of the microbial community intact;
• Introduction of phage therapy instead of repeated antibiotic courses may prevent further selection
of antibiotic-resistant strains;
• Phage preparations were shown to be generally safe and well-tolerated.
1.3. Aims of the Study
In this study, we decided to address several unclear issues regarding the microbiology of AECRS,
such as species diversity and prevalence of antibiotic resistance among the strains isolated from AECRS
patients. The second question concerns the activity of bacteriophages from the Biophage Pharma
collection against the isolated bacteria, especially antibiotic-resistant strains, to evaluate the possibility
of including phage therapy in the treatment of patients with AECRS in the future.
2. Results
Fifty patients with AECRS were included in the study. All of the patients had undergone
endoscopic sinus surgery (ESS). The demographic and clinical characteristics of the study group are
listed in Table 1. The majority of patients who presented with sinonasal infections to the outpatient
clinic of the Department of Otolaryngology, Jagiellonian University Medical College in Krakow, had
CRS with nasal polyps. Most of them had suffered from rhinosinusitis for many years and reported
a long history of topical, and frequently also systemic, steroid treatment. Many had experienced
recurrent exacerbations that required repeated antibiotic courses.
A total of 97 isolates were recovered from the patients. A detailed list of the isolated species
including information about their antibiotic-resistance mechanisms is shown in Figure 1.
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Table 1. Characteristics of the study group. CRS—chronic rhinosinusitis; ESS—endoscopic
sinus surgery.
Gender Male 23 (46%)Female 27 (54%)
Age 25–80 (mean 51)
Nasal polyps 45 (90%)
Comorbidities
Asthma 27 (54%)
Allergy (to pollen, dust mites, etc.) 19 (38%)
Aspirin-exacerbated respiratory disease 10 (20%)
Gastroesophageal reflux 8 (16%)
History of CRS (years) 1.5–45 (median 10)
History of recurrent exacerbations and repeated antibiotic treatment 31 (62%)
Number of prior ESS procedures 1–5 (median 1.5)
Time since the last ESS (months) 1–96 (median 11)
Lund–Mackay computed tomography staging score [29] prior to surgery (total 0–24) 6–24 (median 15)
Modified Lund–Kennedy endoscopic score [30] on enrollment (0–2 for polyps, edema,
discharge on each side, total 0–12) 2–12 (mean 6)
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Mechanisms  of  antibiotic  resistance were  identified  in  28%  of  the  isolates. However, most 
patients harbored several strains (1–4, median 2 per patient), frequently both antibiotic‐sensitive and 
antibiotic‐resistant. Consequently,  antibiotic‐resistant bacteria were  carried by  46% of patients.  If 
both natural and acquired resistance were taken into account, 18% of the isolated strains obtained 
from 28% patients were not sensitive to amoxicillin/clavulanate. Even greater rates of resistance were 
observed for macrolides (25% of strains, 42% of patients) and clindamycin (30% of strains, 40% of 
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Mechanisms of antibiotic resistance were identified in 28% of the isolates. However, most
patients harbored several strains (1–4, median 2 per patient), frequently both antibiotic-sensitive and
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antibiotic-resistant. Consequently, antibiotic-resistant bacteria were carried by 46% of patients. If both
natural and acquired resistance were taken into account, 18% of the isolated strains obtained from
28% patients were not sensitive to amoxicillin/clavulanate. Even greater rates of resistance were
observed for macrolides (25% of strains, 42% of patients) and clindamycin (30% of strains, 40% of
patients). On the other hand, resistance to fluoroquinolones was very uncommon (6% of strains,
10% of patients). Similar results were noted for aminoglycosides (resistance to gentamicin in 4% of
strains and 8% of patients). Reduced sensitivity to carbapenems was detected only in one strain of
Pseudomonas aeruginosa. All of the isolates, including methicillin-resistant Streptococcus aureus (MRSA),
were sensitive to linezolid.
Analysis of the distribution of bacteria in patients with various comorbidities proved that
antibiotic-resistant strains were more frequently isolated from individuals with aspirin-exacerbated
respiratory disease (AERD). In these patients, 53% of the isolated bacteria had antibiotic-resistance
mechanisms compared to 25% in patients without AERD. The difference was statistically significant
(chi-square 5.18, p = 0.02). Similar results were noted for patients with asthma (38% of isolates with
resistance mechanisms versus 17% in patients without asthma, chi-square 5.09, p = 0.02). Also, the
participants who reported recurrent exacerbations more frequently carried resistant strains, however,
this trend did not reach statistical significance. The presence of other comorbidities did not correlate
with any differences in the distribution of bacterial species.
Only in five (10%) patients a pathogen characteristic for acute rhinosinusitis (i.e., Haemophilus
influenzae or Streptococcus pneumoniae) was the only one identified in the swab. In eight (16%) individuals
we found solely bacteria of disputable pathogenicity, such as Staphylococcus epidermidis and other
coagulase-negative staphylococci, Streptococcus viridans or Corynebacterium spp.
Phage typing was performed for Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli,
Klebsiella pneumoniae, Klebsiella oxytoca, and Acinetobacter baumannii. The vast majority (80%) of these
isolates, including antibiotic-resistant strains, were sensitive to the bacteriophages from the collection
used in the study, as shown in Figure 2. Bacteriophages for other bacterial species were not available in
the collection. Bacteria that are traditionally not considered as pathogenic, such as coagulase-negative
staphylococci, corynebacteria, and S. viridans, were not included in phage typing and further analyses.
The remaining bacteria are further briefly referred to as “pathogens”.
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collection, it does not necessarily mean that they are resistant to phages in general. Nevertheless, 59% 
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Figure 2. Sensitivity of S. aureus, P. aeruginosa, E. coli, and Klebsiella spp. to antibiotics and bacteriophages.
Figure 3 compares the sensitivity of the pathogens isolated from the study group to antibiotics and
bacteriophages. The strains were described as ‘antibiotic-resistant’ if they had mechanisms of antibiotic
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resistance and as ‘antibiotic-sensitive’ if no such mechanisms were identified. On the other hand,
although the strains labeled as ‘phage-insensitive’ were not lysed by the phages from our collection,
it does not necessarily mean that they are resistant to phages in general. Nevertheless, 59% of the
pathogens, including 81% of the antibiotic-resistant pathogens, showed sensitivity to bacteriophages.
Phage cocktails proved to be effective against 63% of S. aureus isolates and 40% of P. aeruginosa isolates.
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Figure 3. Comparison of phage and antibiotic sensitivity in the strains considered as “pathogens” (in 
this figure the species of disputable pathogenicity were excluded). S—sensitive, R—resistant. 
As explained above, due to uneven distribution of the bacteria among patients, the prevalence 
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pathogens, 11 (22%) had both phage‐sensitive and phage‐resistant pathogens, and 12 (24%) had only 
phage‐insensitive  pathogens  (as mentioned  above,  the  remaining  8  patients  had  only  strains  of 
disputable pathogenicity). The phage cocktails were effective in 63% of patients with S. aureus and 
40% of patients with P. aeruginosa. 
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3. Discu sion
3.1. Microbiology and Antibiotic Resistance in AECRS
The question how to treat AECRS is frequently encountered in clinical practice, but surprisingly
seldom addressed in research. Currently, there are no evidence-based guidelines for the management
of AECRS [17]. It is still a point of debate whether AECRS should be treated similarly to acute
bacterial rhinosinusitis in patients without underlying chronic sinonasal disease (ABRS). In ABRS, the
usual pathogens are S. pneumoniae, H. influenzae, and Moraxella catarrhalis, and the most commonly
recommended antibiotics are amoxicillin or amoxicillin/clavulanate [31]. Meanwhile, the bacteriology
of AECRS is far from clear. Some authors suggest that the microbiology of ABRS and AECRS can
be similar. In two studies by Brook et al., S. pneumoniae, H. influenzae, and M. catarrhalis were the
most commonly isolated aerobic bacteria in patients with AECRS [18,32]. However, many researchers
share the opinion that the sinonasal microenvironment altered by CRS may impact the evolution
of bacterial infections. Further changes in the microbiome composition and increased antibiotic
resistance are observed after surgery and repeated antibiotic courses. Therefore, patients with AECRS
(particularly after surgery) are likely to harbor different bacterial species and require different therapy
than recommended for ABRS [17,33].
Our observations strongly support the assumption that the bacteriology of AECRS is distinct from
ABRS. In our study, the species identified in more than a half of the isolates were S. aureus, S. epidermidis,
and other coagulase-negative staphylococci, followed by H. influenzae, P. aeruginosa, and less commonly,
E. coli, S. pneumoniae, K. pneumoniae, and K. oxytoca. Overall, the “acute pathogens” S. pneumoniae and
H. influenzae constituted only 9% of the isolates. It is important to note that barely in five patients the
“acute pathogen” was the only one isolated from the sinuses. In most cases it was accompanied by
S. aureus or P. aeruginosa. The significance and pathogenic potential of coagulase-negative staphylococci
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in patients with AECRS remains unclear. In our patients, these species were also usually isolated
together with other bacteria, and only in eight patients no other pathogenic species were identified.
Other authors who investigated populations similar to our study group (mainly post-ESS patients
with correctly diagnosed AECRS) reported comparable findings [34–38]. The most commonly isolated
pathogens were always S. aureus (25%–70%) and P. aeruginosa (9%–24%), while the “acute pathogens”
S. pneumoniae, H. influenzae, and M. catarrhalis constituted only 10%–22% of all isolates. S. epidermidis
was also frequently identified in the isolates (however, some authors considered it nonpathogenic and
did not include it in their calculations). These results suggest that our observations can be considered
as representative for the general population of patients with postoperative exacerbations of CRS.
Antibiotic-resistant bacteria are frequently isolated from patients with CRS [34,39]. In our study
resistant strains were identified in almost half of the patients. The antibiotic sensitivity analysis
indicated that amoxicillin should not be chosen as the first line or empiric treatment for post-ESS
patients with AECRS, because they are likely to harbor strains not sensitive to amoxicillin. This finding
stands in contrast to the recommendations for ABRS [22]. Fluoroquinolones and aminoglycosides
provided the best chance for clinical success in our study group, but they need to be administered with
caution due to their considerable toxicity. Therapeutic decisions in patients with AECRS are, therefore,
not trivial. The patient’s individual contraindications and local patterns of resistance (primarily for
S. aureus and P. aeruginosa) should be considered to choose optimal empiric therapy.
The most probable cause of antibiotic resistance in the patient’s microbiota is repeated antibiotic
therapy in the past. It is not possible to assess retrospectively the number of antibiotic courses that the
patients have received in their life. In our group, there was higher incidence of antibiotic-resistant
strains in patients with self-reported recurrent exacerbations treated with antibiotics, but this result
was not statistically significant. In fact, it is the patients with asthma and particularly AERD who
typically present with the most severe and recalcitrant CRS and receive the most aggressive treatment,
including repeated antibiotic courses. Indeed, as expected, the rates of antibiotic resistance in patients
with asthma and AERD were extremely high. The patients’ medical history seems to be reflected in
their microbiota, which is another argument to support the postulate to avoid the use of antibiotics
unless it is truly necessary.
Many patients in our study group carried bacterial species such as coagulase-negative staphylococci
that are traditionally considered as non-pathogenic but had mechanisms of antibiotic resistance. It is
disputable whether these species can cause symptoms of exacerbations in patients with CRS or if they
should be targeted by treatment. Nevertheless, even if they only constitute a part of the commensal
flora, they may transfer the genes of antibiotic resistance to actual pathogens and thus reduce the
clinical effectiveness of antibiotic therapy.
3.2. Phage Therapy for AECRS
Increasing antibiotic resistance is one of the most important triggers to search for alternative
antimicrobials. Phage therapy is one of the most promising methods that frequently proved to be safe
and effective when antibiotic treatment failed [25,27]. Nowadays, after many decades when it was
almost forgotten in Western countries, the use of bacteriophages is gaining rising interest as a method
that could solve many problems associated with antibiotic treatment.
Phage therapy has not yet been approved for use in exacerbations of CRS, but the results of
preliminary studies and the first clinical trials are very promising [40]. Drilling et al. tested the in vitro
efficacy of a bacteriophage cocktail against S. aureus strains isolated from Australian patients with
CRS [41]. The cocktail lysed 94% (62/66) of the isolates in planktonic forms. Furthermore, the cocktail
caused a reduction in biofilm mass for four out of five of the isolates. Similarly, Fong et al. proved
that a cocktail of four phages was able to lyse 89% (40/45) of P. aeruginosa isolates from CRS patients
from Australia, Europe, and the USA. Again, the cocktail significantly reduced P. aeruginosa biofilms
grown in vitro [42]. Finally, Zhang et al. found that phage susceptibility of S. aureus isolates from CRS
patients was not decreased in the most feared multidrug-resistant pathogens [43].
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The safety and efficacy of the bacteriophages or their enzymes for sinonasal infections was shown
in vivo in murine and ovine models [44–48]. For over a century, phage therapy has also been used
in humans without significant adverse effects and it is still widely used in Georgia and Russia [25].
Nevertheless, in Western countries it is still considered an unapproved treatment method. In Poland,
the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, in Wroclaw
collected vast experience providing phage therapy as experimental treatment to patients with various
recalcitrant bacterial infections, including sinusitis. Application of bacteriophages was shown to be
safe and it was associated with clinical improvement in 77%–83% of patients with sinusitis [49,50].
Recently, a phase 1 clinical trial of a phage cocktail against S. aureus in CRS patients was conducted
in Australia [51,52]. The product was self-administered by nine post-ESS patients, who had failed all
other medical therapies. Out of 25 patients who entered the study and did not declare withdrawal,
9 (36%) harbored bacteria susceptible to the cocktail. Overall, the sensitivity of S. aureus isolates to
the preparation was 80%. The treatment was well tolerated and caused no serious adverse events.
It resulted in reduction of S. aureus growth or eradication of the infection, nevertheless, it did not
cause significant alleviation of symptoms. As discussed earlier, symptomatic improvement could
probably be more apparent in cases of recent acute exacerbation than in patients with longstanding
and recalcitrant baseline symptoms of CRS.
To assess the potential applicability of phage therapy in the population of patients with post-ESS
AECRS, we decided on a different approach than in the in vitro studies described above. Instead of
selecting one bacterial species for phage typing, we prospectively tested the phage sensitivity of all
bacterial strains isolated from 50 consecutive patients who presented with relevant signs and symptoms.
The results seem to be encouraging.
Generally, the products used for phage therapy can be either patient-tailored or preformed.
The first approach requires phage typing of bacteria isolated from the patient and application of a
custom-produced bacteriophage preparation. The second method utilizes broad spectrum cocktails
that contain several bacteriophages active against various strains. In our study group, individualized
therapy with phages selected from the collection could potentially be used in 60% of patients.
Thirty-eight percent of the patients could potentially be treated solely with bacteriophages, as they
carried only phage-sensitive pathogens. In 22% of patients, bacteriophages could be used as an adjunct
to antibiotics, as both phage-sensitive and phage-resistant pathogens occurred together. Ready phage
mixtures against S. aureus and P. aeruginosa would be suitable for 40% of patients. The most important
findings of our study concern the phage susceptibility of antibiotic-resistant strains in the population of
patients with AECRS. Eighty-one percent of these strains were sensitive to phages from the collection.
3.3. Limitations of the Study
• Culture provides limited information compared to molecular methods that would allow for more
profound analysis of the microbiota in AECRS [13]. Culture-dependent techniques were utilized in
this study because they were required for phage typing, which was the essential part of the project.
• The current study did not include identification of anaerobes; further research is required to
address this problem.
• Phage susceptibility testing was limited to the contents of the collection available for our study.
However, the collection is still being developed and there is a possibility of phage isolation
on demand.
• Further research is required to test the phage sensitivity of bacteria in biofilms and in
polymicrobial communities.
4. Materials and Methods
The study protocol was approved by the Jagiellonian University Medical College Bioethics
Committee (registry no: 1072.6120.208.2017). Written informed consent was obtained from all
participants prior to enrollment.
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4.1. Patient Recruitment
Adult patients with AECRS were recruited from the outpatient clinic of the Department of
Otolaryngology, Jagiellonian University Medical College in Krakow between May 2018 and May
2019. The diagnosis of CRS was made based on the diagnostic criteria of the EPOS guidelines [22].
All of the participants had undergone endoscopic sinus surgery (post-ESS patients). AECRS was
diagnosed according to the criteria suggested by Orlandi et al. [17] (worsening of symptoms and
purulence on endoscopic examination, which usually was accompanied by crusting, hyperemic, and
edematous mucosa and frequently polyp formation). If the history, symptoms, and endoscopic findings
suggested a nonbacterial etiology of the exacerbation, such as allergy or viral infection, the patient was
excluded from the study. Patients were also not enrolled if they had received any systemic or topical
antibiotics in the week preceding sample collection or fulfilled the EPOS criteria of exclusion from
general studies [22].
4.2. Specimen Collection
The swabs were collected directly from the infected sinuses under endoscopic guidance (in most
postoperative patients the cavities were readily accessible for sample collection). As recommended
by Nadel et al. [53], the swabs were placed directly into the pathological secretions. Contamination
from the nares was carefully avoided and any swabs that could have come into contact with the nasal
vestibule were discarded. The specimens were delivered to the laboratory as soon as possible after
collection. Specimens for bacterial culture were transported at 4 ◦C in Amies medium.
4.3. Bacterial Culture and Identification
The swabs were inoculated on the Columbia agar with 5% sheep blood (OXOID) for Gram-positive
aerobic cocci and on the selective MacConkey agar (OXOID) for the isolation of Gram-negative bacilli
and the chocolate base agar with bacitracin (OXOID) for the isolation of Haemophilus. After 18 to
24 hours of incubation at 37 ◦C in the atmosphere containing 5% CO2, bacterial colonies were isolated
and identified. Microorganisms were identified using a BD Phoenix (Becton Dickinson) automated
microbiology system and appropriate test kits dedicated for Gram-negative and Gram-positive bacteria.
Haemophilus rods were identified with discs containing bacitracin and factors V and X on Müller–Hinton
agar plates (OXOID) by incubating a McFarland 0.5 suspension with paper discs for 24 hours at 37 ◦C
with access to CO2.
4.4. Determination of Antibiotic Resistance
Bacterial isolates were tested according to EUCAST (The European Committee on Antimicrobial
Susceptibility Testing) version 6.0 [54], using disc diffusion methodology on Müller–Hinton agar plates
(OXOID). Clinical breakpoints for bacteria were interpreted according to EUCAST v. 8.0. [55,56].
4.5. Phage Typing—Spot Test
The bacteriophages used for phage typing belonged to the collection of Biophage Pharma S.A.
and included phages specific for: S. aureus, P. aeruginosa, E. coli, A. baumannii, and K. pneumoniae (used
also for typing of K. oxytoca), as well as two phage cocktails specific for S. aureus and P. aeruginosa (each
containing four selected phages) [57,58]. The cocktail consisting of S. aureus phages was prepared with
the phages Puł/14/14256, Kr/6/1934, W/5/14256, and Kos/10/22119 at a concentration of 108 PFU/mL per
phage. The electron microscopy scan showed that all bacteriophages belong to the Myoviridae family.
The cocktail consisting of P. aeruginosa phages was prepared with the phages Kos/4/1815, Ku/89/1815,
Jar/51/2117, and P/53/2117. The cocktail was composed of phages mixed at the same number of PFU
per milliliter (108 PFU/mL). The electron microscopy scan showed that the phage Jar/51/2117 belongs
to the Podoviridae family, and the three remaining phages belong to the Myoviridae family.
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Bacteriophages specific for other species isolated from the patients were not available in
the collection.
A spot test was used as a method for determination of the bacteriophage’s host range in the
bacterial collection [59–61]. The tested bacterial strains were grown in NZCYM broth (to the turbidity
0.5 McFarland). Three milliliters of molten soft agar (0.7%) was mixed with 100 µL of the bacterial
cells and this mixture was then overlaid onto the surface of solidified basal NZCYM agar (1.5%). Ten
microliters (about 1.0 × 108 PFU/mL) of a phage suspension was spotted onto bacterial lawn, which was
then incubated overnight at 37 ◦C. Bacterial sensitivity to bacteriophage was established by bacterial
lysis at the spot where the phage was deposited. Each test was repeated two times. According to the
degrees of clarity, the spots were differentiated into following categories:
• n—no clearing—no bacterial lysis in the spot;
• p—a few single plaques in the spot;
• o3—turbid spot—very weak bacterial lysis in the spot;
• o2—medium turbid spot—weak bacterial lysis in the spot;
• o1—almost clear spot—very weak bacterial growth in the spot;
• c—completely clear spot—complete bacterial lysis in the spot.
Bacterial strains were described as phage-sensitive if the typing results fell into the categories c,
o1, or o2.
5. Conclusions
In this study we have demonstrated that S. aureus, H. influenzae, P. aeruginosa, and Enterobacteriaceae
are the species most commonly cultured from the patients with post-ESS AECRS. Disturbingly, in 28%
of isolated species we detected mechanisms of antibiotic resistance. Our observations suggest that due
to different microbiology and frequent resistance of the pathogens to amoxicillin, treatment of AECRS
should not follow the recommendations for ABRS. The lowest rates of resistance were observed for
fluoroquinolones and aminoglycosides. Fortunately, 59% of the pathogens isolated from the patients
were sensitive to phages, including 81% of the antibiotic-resistant bacteria. Phage preparations that
could be used instead of, or as an adjunct to, antibiotics are currently available for at least 60% of
patients with AECRS. Preformed phage cocktails that could potentially be introduced without previous
typing could be effective in 63% of patients with S. aureus infections and 40% of patients with P.
aeruginosa infections. Definitely, further expansion of the phage collection is necessary to address
infections caused by less common pathogens.
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